-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485

Benzinga·10/22/2026 18:06:59
Listen to the news
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $485.